Cargando…
Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates
Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1‐like1 inhibitor, ezetimibe (Ez)....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055037/ https://www.ncbi.nlm.nih.gov/pubmed/27761360 http://dx.doi.org/10.1002/2211-5463.12107 |
_version_ | 1782458712639668224 |
---|---|
author | Deushi, Michiyo Osaka, Mizuko Nakano, Kaku Osada, Kyoichi Egashira, Kensuke Yoshida, Masayuki |
author_facet | Deushi, Michiyo Osaka, Mizuko Nakano, Kaku Osada, Kyoichi Egashira, Kensuke Yoshida, Masayuki |
author_sort | Deushi, Michiyo |
collection | PubMed |
description | Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1‐like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5‐year‐old males) were fed either regular cholesterol + high‐fat diet (control‐HFD) or oxysterols + high‐fat diet (ox‐HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control‐HFD, ox‐HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g(−1) (ox‐HFD) versus 3.2 (control‐HFD) mg·g(−1); triglycerides, 28.0 (ox‐HFD) versus 5.7 (control‐HFD) mg·g(−1)]. Ox‐HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control‐HFD. We then examined the effects of Ez, 0.2 mg·kg(−1)·day(−1) for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia. |
format | Online Article Text |
id | pubmed-5055037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50550372016-10-19 Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates Deushi, Michiyo Osaka, Mizuko Nakano, Kaku Osada, Kyoichi Egashira, Kensuke Yoshida, Masayuki FEBS Open Bio Research Articles Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1‐like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5‐year‐old males) were fed either regular cholesterol + high‐fat diet (control‐HFD) or oxysterols + high‐fat diet (ox‐HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control‐HFD, ox‐HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g(−1) (ox‐HFD) versus 3.2 (control‐HFD) mg·g(−1); triglycerides, 28.0 (ox‐HFD) versus 5.7 (control‐HFD) mg·g(−1)]. Ox‐HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control‐HFD. We then examined the effects of Ez, 0.2 mg·kg(−1)·day(−1) for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia. John Wiley and Sons Inc. 2016-09-20 /pmc/articles/PMC5055037/ /pubmed/27761360 http://dx.doi.org/10.1002/2211-5463.12107 Text en © 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Deushi, Michiyo Osaka, Mizuko Nakano, Kaku Osada, Kyoichi Egashira, Kensuke Yoshida, Masayuki Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title_full | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title_fullStr | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title_full_unstemmed | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title_short | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
title_sort | ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055037/ https://www.ncbi.nlm.nih.gov/pubmed/27761360 http://dx.doi.org/10.1002/2211-5463.12107 |
work_keys_str_mv | AT deushimichiyo ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates AT osakamizuko ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates AT nakanokaku ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates AT osadakyoichi ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates AT egashirakensuke ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates AT yoshidamasayuki ezetimibereducedhepaticsteatosisinducedbydietaryoxysterolsinnonhumanprimates |